Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients
Elisabetta Schiaroli(University of Perugia), Daniela Francisci(University of Perugia), Antonella Mencacci(University of Perugia), Roberta Spaccapelo(University of Perugia), Barbara Camilloni(University of Perugia), Carlo Pallotto(University of Perugia), Sabrina Bastianelli(University of Perugia), Lisa Malincarne(University of Perugia), Sara Pierucci(University of Perugia), Giuseppe Vittorio De Socio(University of Perugia), Chiara Busti(University of Perugia), Giovanni Brachelente(Ospedale Santa Maria), Alfredo Villa(Ospedale Santa Maria), Giulia Bicchieraro(University of Perugia), Flavio Falcinelli(University of Perugia), Anna Gidari(University of Perugia)
Cited by 3
Related Papers
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years
|BMC Geriatrics|2018|179
Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice
|The Journal of Immunology|1997|175
Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection
|Scandinavian Journal of Infectious Diseases|2020|117
Aortic Stiffness in Untreated Adult Patients With Human Immunodeficiency Virus Infection
|Hypertension|2008|108